When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
September 17, 2021
Fiat Lux
Featured Trade:
(WHY TECHNICAL ANALYSIS IS A DISASTER)
(THE COOLEST TOMBSTONE CONTEST)
(SJB), (JNK), (HYG)
Mad Hedge Bitcoin Letter
September 16, 2021
Fiat Lux
Featured Trade:
(ONE OF AMERICA’S DIRTY LITTLE SECRETS)
(BTC)
Mad Hedge Biotech & Healthcare Letter
September 16, 2021
Fiat Lux
FEATURED TRADE:
(RIDING THE COVID-19 VACCINE MOMENTUM)
(PFE), (BNTX), (MRNA), (JNJ), (SNY), (GSK), (TRIL)
Crypto is quite controversial — almost a concept that is too much for the average joe.
People argue about the very existence of it — whether it deserves to be a zero or deserves to be at $100,000 and everything in between.
Then there is the angry Gen Z and Millennial cohort who love to say:
“Well of course the economy is screwed because nobody wants to pay a decent salary, and nobody wants to work.”
They go on to say that “paper money is worthless if there is nothing to buy because nothing is produced.”
If one is to believe the economy is compromised, then it suggests that an alternative ideology must be embraced.
Crypto has entered that void.
The origins of these thoughts come from the U.S. outsourcing manufacturing to far-flung places around the globe and to compensate for that, the US central bank has undergone quantitative easing like there is no tomorrow.
Instead of paying high wages in the U.S., that bill is cut by taking advantage of offshore wages.
The Mad Hedge IT staff is mainly based in emerging markets so it’s not like I can say I am not dipping my toe in wage arbitrage either.
Many companies are doing it — it’s almost normal these days.
One of America’s dirty secrets is the growing contempt for the status quo as many young people feel like the world is against them.
Property cost 10x what their parents paid while real wages have decreased even if they have increased nominally.
The cost of living is becoming insane or rather is insane.
Even with a well-paying job, many find themselves living paycheck to paycheck and in credit card debt.
This has triggered many to invest in crypto while trying to manage student debt the best they can.
A 9-5 is never going to allow anyone to become "well off" like the case in past American generations which is why I brought up the alternative ideology.
It’s real and it’s happening as we speak.
Young people are searching for that launchpad that will take them to luxury and the most valid test case is increasingly becoming different types of crypto.
It’s that right now one can earn a few nickels from a savings account thanks to the brilliant 0.01% interest rates banks give.
Many earned more investing in crypto coins this year than the last 10, 20, 30 years of life in a savings account.
Granted, 401k gets about 10% a year but this is nowhere enough to retire with uncontrollable living costs.
Take a better case of a 30-year-old employed as a purchaser for a medium-sized company for 10 years and he or she managed to buy a condo but not a single-family house yet while being financially still well off.
It is possible to ride that corporate ladder, just not as fast and easy as it was 30 years ago and only in selective cities.
This is a more optimistic take on the current situation, yet I would bet crypto is still a legitimate option for someone with this financial profile because even with a better scenario, finances aren’t good enough if you extrapolate it far into the future relative to the economic challenges they face ahead.
We live in a culture of get-rich-quick that has been exacerbated by technology and platforms that have us chronicling our lives every millisecond.
Even if the grind has been largely positive for 10 years of working full time, many are still viewing crypto as the last resort to a timely retirement.
Time is of the essence, why?
The IRS could come in and make the asset unattractive.
At this point I do believe it is getting too big to fail and at $2 trillion market cap, is the IRS willing to wipe that off the books of mostly Gen Z and Millennials who mostly have marginal net worth?
That would be adding insult to injury, but don’t call me a snowflake for saying it.
But young people need a way to actually... own part of this world too whether it’s a digital code or something else.
This idea is increasingly rubbing up against the status quo of the asset smash and grab fest that fiat-based assets and low interest rates facilitated and many young people were just that, simply too young to participate in.
Don’t blame it on anyone.
The 99% are just trying to get by.
That goes to say that as a whole, the US has the best standard of living of anywhere in the world for average people in the population, the same can’t be said if one were to have been born in Bangladesh, India, or Sub-Saharan Africa.
And rich countries have no incentive to support crypto full stop because the U.S. has the U.S. dollar which is still the reserve currency of the world instead of a banana republic like El Salvador who has aggressively pivoted into crypto assets.
Many young people want the system to take a turn around and accommodate them, but that will not happen.
If crypto does lead to a huge transfer of wealth then it'll still be going to those with enough spare cash to take the risk of investing. Most people who really need the resources are not investing in crypto, they're paying for food and shelter, so they aren’t stuck on the street with no roof over their head.
The getting is good NOW, and growth rates will severely moderate if the government feels too left out of the bonanza.
No need to over or under-hype this phenomenon.
An asset with unbelievable growth rates now that are invested in by people who have liquid cash whether it be institutions, college kids, or the middle class.
Crypto is not a secret passport to extravagant dreams.
It’s simply a strengthening asset in the early innings of a growth cycle and the lack of regulation acts as a supercharger like it did to Facebook, Google, Apple, and Microsoft when they were in the early innings’ of their growth phase.
The pandemic is exhibiting hints of easing, and one of the names playing a critical role in the vaccine rollout that has made this step towards normalcy possible is Pfizer (PFE).
Actually, Pfizer stock has hit an all-time high courtesy of its COVID-19 vaccine, Comirnaty, which it developed with German biotech firm BioNTech (BNTX).
While this is undoubtedly an exciting time for the company, many investors wonder whether this period also marks the spectacular of Pfizer, and things will go downhill from here. After all, several of its patents are set to expire starting in 2025.
My short answer to this question is no. This isn’t the beginning of the end for Pfizer. Looking at the company’s history, pipeline, and trajectory, I can say that Pfizer’s rise is just getting started.
One of the key reasons behind my belief is Pfizer’s robust pipeline.
To date, the company has roughly 100 drugs queued for regulatory clearance, while others are slated for late-stage clinical testing.
That means that regardless of the patent expirations in Pfizer’s horizon, the company’s strong and diverse pipeline can easily counteract the blow from the loss of exclusivity.
Just last month, Pfizer received full approval from the US FDA for Comirnaty.
Since fellow vaccine developers like Moderna (MRNA) have yet to achieve the same, this makes Pfizer the first COVID-19 vaccine to gain this endorsement from the regulatory committee.
Needless to say, Pfizer could capitalize on this massive opportunity to boost its profits in the quarters.
The availability of a fully approved COVID-19 vaccine could allow establishments to oblige mandatory vaccinations, which could obviously lead to higher demand for Comirnaty, as over 100 million Americans have yet to receive at least a single jab.
In the second quarter of 2021, the company reported $19 billion in revenue, indicating a 92% year-over-year climb thanks to the $7.8 billion raked in by its COVID-19 vaccine.
Pfizer now estimates Comirnaty revenue to reach roughly $33.5 billion, indicating an expected 2.1 billion doses to be delivered within the year.
Excluding Comirnaty’s sales, Pfizer’s revenue increased by 10%. This strong momentum led the company to raise its 2021 full-year guidance to somewhere between $78 and $80 billion.
Before Comirnaty, though, Pfizer had already been known as a prolific vaccine developer.
One of its prized creations is the pneumococcal vaccine Prevnar, which generated $2.52 billion in revenue in the first 6 months of 2021.
Meanwhile, its tick-borne encephalitis vaccine, marketed as TicoVac, gained FDA approval in July and could bring in roughly $1 billion per annum.
Riding this momentum, Pfizer has been busy developing another potential moneymaker in this segment in the form of its respiratory syncytial virus (RSV) vaccine candidate: RSVpreF.
And if the Phase 3 results for RSVpreF come anywhere near its Phase 2 trial, then Pfizer has another blockbuster in its hands.
This is because the RSV vaccine market is projected to grow to approximately $10 billion by 2030, and Pfizer’s candidate is targeting 72% of that population.
However, the RSV market will be a crowded space with the likes of Johnson & Johnson (JNJ), Sanofi (SNY), and GlaxoSmithKline (GSK) working to fill this unmet medical demand.
So, realistically, Pfizer’s RSVpreF has the potential to capture 20% market share, translating to $2.1 billion in annual revenue.
Apart from its vaccine-related efforts, Pfizer’s core businesses have been growing as well. Top contributors come from its oncology arm, specifically Eliquis and Ibrance.
Its recent acquisition of Trillium Therapeutics (TRIL) is anticipated to serve as a catalyst for Pfizer’s cancer segment in the next years as well.
Overall, Pfizer has a blockbuster drug pipeline and an impressively successful COVID-19 vaccine rollout. These provide the company with a long runway for solid and steady growth.
“Bitcoin is like anything else: it's worth what people are willing to pay for it.” – Said Hedge Fund Manager Stanley Druckenmiller
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
September 16, 2021
Fiat Lux
Featured Trade:
(TRADING FOR THE NON-TRADER),
(ROM), (UXI), (UCC), (UYG)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.